Usa virus covid-19 prevention infection Usa

Gilead’s remdesivir prevents Covid-19 progression in preclinical study

Reading now: 649
www.pharmaceutical-technology.com

A preclinical study in the US found that Gilead Sciences’ antiviral drug candidate remdesivir prevented disease progression in rhesus macaques monkeys with Covid-19.

The animals were infected with the novel coronavirus, SARS-CoV-2. Data announced by the National Institutes of Health (NIH) revealed a significant decrease in clinical disease and reduced lung damage in monkeys treated with the investigational antiviral drug.

The preclinical study involved dosing and treatment procedures being used in a clinical trial of remdesivir to treat hospitalised Covid-19 patients.

NIH’s National Institute of Allergy and Infectious Diseases (NIAID) is leading the trial. In the preclinical study, one group of monkeys were given remdesivir while the

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA